<DOC>
	<DOCNO>NCT02189720</DOCNO>
	<brief_summary>The primary objective study : • To provide patient LEMS/CMS/downbeat nystagmus access amifampridine phosphate therapy product become commercially available . The secondary objective study : • To assess long-term safety amifampridine phosphate patient LEMS/CMS/downbeat nystagmus</brief_summary>
	<brief_title>Expanded Access Study Amifampridine Phosphate Lambert-Eaton Myasthenic Syndrome ( LEMS ) , Congenital Myasthenic Syndrome ( CMS ) , Downbeat Nystagmus Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>Nystagmus , Pathologic</mesh_term>
	<mesh_term>Myasthenic Syndromes , Congenital</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Male female : 2 year age 5 pediatric CMS study sit 10 year age study site . Confirmed physician diagnosis LEMS , CMS downbeat nystagmus . Completion anticancer treatment least 3 month ( 90 day ) treatment . Negative urine pregnancy test female childbearing potential Screening . If sexually active childbearing potential , willing use 2 acceptable method contraception screen visit 3 month last dose investigational product . No adequate clinical data expose pregnancy available amifampridine . No nonclinical safety data available regard effect amifampridine reproductive function . Amifampridine phosphate use pregnancy . It unknown whether amifampridine excrete human breast milk . The excretion amifampridine milk study animal . Amifampridine phosphate use breastfeeding . Any subject currently participate study LMS002 , LMS002EXT , CMS 001 immediately eligible enrollment study EAP001 , long inclusion/exclusion criterion still meet . Willing able provide write informed consent nature study explain start researchrelated procedure . History epilepsy . CMS subtypes include slowchannel syndrome , LRP4 deficiency , acetylcholinesterase deficiency . Known active brain metastasis . Patients treat brain metastasis ( radiotherapy and/or surgery ) complete treatment brain metastasis &gt; 90 day Screening , neurologically stable ( neurological symptom grade &lt; 1 ) , stable dose corticosteroid evidence new disease magnetic resonance imaging ( MRI ) eligible , provide meet inclusion/exclusion criterion . Current use dalfampridine ( Ampyra® ; 4aminopyridine ) , form 3,4 DAP investigational product provide , amifampridine base agree discontinue use duration study . Use guanidine hydrochloride within 7 day start amifampridine phosphate treatment . History drug allergy pyridinecontaining substance amifampridine phosphate excipients ( i.e . microcrystalline cellulose , colloidal silicon dioxide calcium stearate ) . Use investigational product ( 3,4 DAP amifampridine phosphate ) investigational medical device within 30 day start treatment requirement investigational agent completion schedule study assessment . An electrocardiogram ( ECG ) within 6 month start treatment show clinically significant abnormality ( y ) , opinion patient 's personal physician . History additional risk factor torsade de pointes ( e.g . history survive near drown due loss consciousness , family history congenital QT syndrome , long QT syndrome , family history unexplained early sudden death , heart failure ) . Breastfeeding pregnant plan become pregnant ( self partner ) . Male patient breastfeed partner exclude study . History severe renal impairment evidence severe renal impairment time Screening laboratory test , specifically creatinine clearance &lt; 30 mL/min ( within 30 day ) calculate use Cockcroft Gault formula . History time Screening laboratory test ( within 30 day ) indicate hepatic impairment : In patient without liver metastasis cancer , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , and/or total bilirubin &gt; 1.5 × upper limit normal ( ULN ) . Any condition , view Principal Investigator , place patient high risk poor treatment compliance complete study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Amifampridine Phosphate</keyword>
	<keyword>Amifampridine</keyword>
	<keyword>3,4-Diaminopyridine Phosphate</keyword>
	<keyword>3,4-Diaminopyridine</keyword>
	<keyword>3,4-DAP</keyword>
	<keyword>LEMS</keyword>
	<keyword>CMS</keyword>
	<keyword>Lambert-Eaton Myasthenic Syndrome</keyword>
	<keyword>Congenital Myasthenic Syndrome</keyword>
	<keyword>Neuromuscular disorder</keyword>
	<keyword>Neuromuscular</keyword>
	<keyword>eye movement</keyword>
	<keyword>electromyography</keyword>
	<keyword>EMG</keyword>
	<keyword>Expanded Access</keyword>
	<keyword>Firdapse®</keyword>
	<keyword>Downbeat Nystagmus</keyword>
</DOC>